We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Teva Pharmaceutical Industries announced that the FDA has approved its abbreviated new drug application for moexipril HCl/hydrochlorothiazide tablets, 7.5 mg/12.5 mg, 15 mg/12.5 mg and 15 mg/25 mg.
Callisto Pharmaceuticals has begun dosing patients in a Phase I clinical trial of L-Annamycin in children and young adults with refractory or relapsed acute lymphocytic leukemia (ALL) or acute myelogenous leukemia (AML).
Biogen Idec and PDL BioPharma have announced that the ongoing CHOICE trial, a Phase II, randomized, double-blind, placebo-controlled trial of daclizumab, met its primary endpoint in a trial involving relapsing multiple sclerosis (MS) patients being treated with interferon beta.
Diamyd Medical has announced details of its Phase III clinical protocol for Diamyd, the company's lead drug candidate for the treatment of autoimmune diabetes, Type 1 diabetes and latent autoimmune diabetes of adults (LADA).
Depomed announced that it has completed patient enrollment in a pivotal registration Phase III clinical trial designed to evaluate the safety and efficacy of Gabapentin GR for the treatment of postherpetic neuralgia.